Literature DB >> 35936132

Building Body With Anabolics Is Weakening the Heart: Anabolic Steroid Induced Cardiomyopathy.

Pradnya Brijmohan Bhattad1, Mazen Roumia1.   

Abstract

Anabolic steroid (AS) use is common in young males, with several reports of various adverse cardiovascular events in the users of AS. We present a unique case of a young male with no other risk factors who developed dilated cardiomyopathy secondary to abuse of AS. The exact mechanism by which AS leads to cardiomyopathy is not very well understood. No specific guidelines have been developed yet with regard to the management of AS-induced cardiomyopathy currently. Adverse events from AS must be promoted to increase awareness in the general and medical population.
Copyright © 2022, Bhattad et al.

Entities:  

Keywords:  anabolic steroids; dilated cardiomyopathy; heart failure; left ventricular dysfunction; myocardial toxicity

Year:  2022        PMID: 35936132      PMCID: PMC9352142          DOI: 10.7759/cureus.26579

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  10 in total

Review 1.  Anabolics and cardiomyopathy in a bodybuilder: case report and literature review.

Authors:  Christoph Ahlgrim; Maya Guglin
Journal:  J Card Fail       Date:  2009-02-10       Impact factor: 5.712

2.  Anabolic steroid use as the possible precipitant of dilated cardiomyopathy.

Authors:  P C Ferrera; D L Putnam; V P Verdile
Journal:  Cardiology       Date:  1997 Mar-Apr       Impact factor: 1.869

Review 3.  Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.

Authors:  Biykem Bozkurt; Monica Colvin; Jennifer Cook; Leslie T Cooper; Anita Deswal; Gregg C Fonarow; Gary S Francis; Daniel Lenihan; Eldrin F Lewis; Dennis M McNamara; Elfriede Pahl; Ramachandran S Vasan; Kumudha Ramasubbu; Kismet Rasmusson; Jeffrey A Towbin; Clyde Yancy
Journal:  Circulation       Date:  2016-11-03       Impact factor: 29.690

4.  Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.

Authors:  P D Thompson; E M Cullinane; S P Sady; C Chenevert; A L Saritelli; M A Sady; P N Herbert
Journal:  JAMA       Date:  1989-02-24       Impact factor: 56.272

5.  Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use.

Authors:  Aaron L Baggish; Rory B Weiner; Gen Kanayama; James I Hudson; Michael T Lu; Udo Hoffmann; Harrison G Pope
Journal:  Circulation       Date:  2017-05-23       Impact factor: 29.690

6.  Characteristics and outcome of patients with heart failure due to anabolic-androgenic steroids.

Authors:  Eva Bjerre Søndergaard; Jens Jakob Thune; Finn Gustafsson
Journal:  Scand Cardiovasc J       Date:  2014-12       Impact factor: 1.589

7.  Supra-physiological dose of testosterone induces pathological cardiac hypertrophy.

Authors:  Prapawadee Pirompol; Vassana Teekabut; Wattana Weerachatyanukul; Tepmanas Bupha-Intr; Jonggonnee Wattanapermpool
Journal:  J Endocrinol       Date:  2016-02-05       Impact factor: 4.286

8.  [Dilated cardiomyopathy in a user of anabolic steroids].

Authors:  P V Schollert; P M Bendixen
Journal:  Ugeskr Laeger       Date:  1993-04-19

Review 9.  Effects of androgenic-anabolic steroids in athletes.

Authors:  Fred Hartgens; Harm Kuipers
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

10.  Effects of graded doses of testosterone on erythropoiesis in healthy young and older men.

Authors:  Andrea D Coviello; Beth Kaplan; Kishore M Lakshman; Tai Chen; Atam B Singh; Shalender Bhasin
Journal:  J Clin Endocrinol Metab       Date:  2007-12-26       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.